3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Sarcoma
9
Osteosarcoma
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Neuroblastoma
3
Neoplasms
3
Medulloblastoma
3
Glioma
3
Ependymoma
3
Central Nervous System Neoplasms
3
Carcinosarcoma
3
Wilms Tumor
2
Rhabdoid Tumor
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Endometrioid
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pathologic Complete Response
1
Interventions
Doxorubicin
17
Cyclophosphamide
16
Ifosfamide
11
fludarabine
9
Radiotherapy
8
tazemetostat
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
pegfilgrastim
3
cixutumumab
3
Trabectedin
3
Radiation
3
Imatinib Mesylate
3
Filgrastim
3
Docetaxel
3
Dacarbazine
3
sargramostim
2
liposomal doxorubicin
2
fludarabine phosphate
2
brostallicin
2
aldesleukin
2
X-Rays
2
Sunitinib
2
Specimen Handling
2
Sorafenib
2
Radiation Dose Hypofractionation
2
Quality of Life
2
Nivolumab
2
Molecular Diagnostic Techniques
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Synovial
×
olaparib
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled